Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17142633 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HTR1AKDM4EALOX15POLB | |
| SCHEMBL17148081 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HTR1AKDM4EALOX15POLB | |
| SCHEMBL17142474 | 0.88 | HTR1A (0.48) | ALDH1A1HTR1AKDM4EPOLBTSHR | |
| SCHEMBL3899323 | 0.87 | — | — | |
| SCHEMBL10064189 | 0.87 | — | — | |
| SCHEMBL4676923 | 0.87 | — | — | |
| SCHEMBL3087289 | 0.86 | HTR1A (0.47) | ALDH1A1HTR1AKDM4EPOLBTSHR | |
| SCHEMBL29714780 | 0.83 | — | — | |
| SCHEMBL12193442 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HTR1AKDM4EPOLBTSHR | |
| SCHEMBL12193444 | 0.81 | ALDH1A1 (0.49) | ALDH1A1HTR1AKDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122050-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-04 | — | — | US | disclosed |
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| CN-116802184-A | Pyrazolothiazole carboxamides and their use as PDGFR inhibitors | 埃科特莱茵药品有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230250094-A1 | SMALL MOLECULE INHIBITORS OF TDP-43 ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-08-10 | — | — | US | disclosed |
| US-20230250094-A1 | SMALL MOLECULE INHIBITORS OF TDP-43 ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-08-10 | — | — | US | disclosed |
| US-20230250094-A1 | SMALL MOLECULE INHIBITORS OF TDP-43 ACTIVITY AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-08-10 | — | — | US | disclosed |
| US-7557215-B2 | Anthraquinone compounds as anti cancer compounds | SOMANTA LIMITED (GB) | 2009-07-07 | — | — | US | disclosed |
| EP-1701939-B1 | ANTHRAQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | SOMANTA LTD (GB) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008062252-A1 | N-OXIDES OF CYTOTOXIC ANTHRAQUINONES AS HYPOXIA-TARGETING PRODRUGS IN CANCER TREATMENT | ACCESS PHARMACEUTICALS, INC (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080027107-A1 | Antharquinone Compounds as Anti Cancer Compounds | SOMANTA LIMITED (GB) | 2008-01-31 | — | — | US | disclosed |
| EP-1858836-A1 | ANALOGUES OF THE AZINOMYCINS AS ANTI-TUMOUR AGENTS AND AS PRODRUGS | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007129195-A2 | 4-PYRIMIDINE-5-AMINO-PYRAZOLE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| CN-1934079-A | Anthraquinone compounds as anti cancer compounds | SOMANTA LTD (GB) | 2007-03-21 | — | — | CN | disclosed |
| WO-2006097730-A1 | ANALOGUES OF THE AZINOMYCINS AS ANTI-TUMOUR AGENTS AND AS PRODRUGS | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2006-09-21 | — | — | WO | disclosed |
| EP-1701939-A1 | ANTHRAQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | Somanta Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005061453-A1 | ANTHARQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | SOMANTA LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027107-A1 | Antharquinone Compounds as Anti Cancer Compounds | TOP2A, TOP2B, RECQL | ALDH1A1 1484/4885HTR1A 1615/4885KDM4E 1024/4885 |
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | ALDH1A1 1872/4885HTR1A 2625/4885KDM4E 2451/4885 |
| US-20230250094-A1 | SMALL MOLECULE INHIBITORS OF TDP-43 ACTIVITY AND USES THEREOF | TARDBP, TDP1, TDP2 | ALDH1A1 2936/4885HTR1A 659/4885KDM4E 2791/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | ALDH1A1 1697/4885HTR1A 2693/4885KDM4E 2332/4885 |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | CSF1R, CD209, NFATC1 | ALDH1A1 3818/4885HTR1A 3902/4885KDM4E 276/4885 |
| US-20240109917-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | PDGFRA, PDGFRB, ABL1 | ALDH1A1 916/4885HTR1A 727/4885KDM4E 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.